ID   INCE_HUMAN              Reviewed;         918 AA.
AC   Q9NQS7; A8MQD2; Q5Y192;
DT   23-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   04-NOV-2008, sequence version 3.
DT   28-JUN-2023, entry version 189.
DE   RecName: Full=Inner centromere protein;
GN   Name=INCENP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND VARIANT
RP   ASP-644.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=11453556; DOI=10.1007/s004120100130;
RA   Adams R.R., Eckley D.M., Vagnarelli P., Wheatley S.P., Gerloff D.L.,
RA   Mackay A.M., Svingen P.A., Kaufmann S.H., Earnshaw W.C.;
RT   "Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and
RT   is overexpressed in tumour cells.";
RL   Chromosoma 110:65-74(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH AURKB
RP   AND AURKC, SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-195, AND VARIANT
RP   ASP-644.
RC   TISSUE=Testis;
RX   PubMed=15316025; DOI=10.1074/jbc.m403029200;
RA   Li X., Sakashita G., Matsuzaki H., Sugimoto K., Kimura K., Hanaoka F.,
RA   Taniguchi H., Furukawa K., Urano T.;
RT   "Direct association with inner centromere protein (INCENP) activates the
RT   novel chromosomal passenger protein, Aurora-C.";
RL   J. Biol. Chem. 279:47201-47211(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ASP-644.
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH CBX3.
RX   PubMed=9864353; DOI=10.1083/jcb.143.7.1763;
RA   Ainsztein A.M., Kandels-Lewis S.E., Mackay A.M., Earnshaw W.C.;
RT   "INCENP centromere and spindle targeting: identification of essential
RT   conserved motifs and involvement of heterochromatin protein HP1.";
RL   J. Cell Biol. 143:1763-1774(1998).
RN   [7]
RP   INTERACTION WITH TUBULIN BETA CHAIN.
RX   PubMed=11139336; DOI=10.1006/excr.2000.5088;
RA   Wheatley S.P., Kandels-Lewis S.E., Adams R.R., Ainsztein A.M.,
RA   Earnshaw W.C.;
RT   "INCENP binds directly to tubulin and requires dynamic microtubules to
RT   target to the cleavage furrow.";
RL   Exp. Cell Res. 262:122-127(2001).
RN   [8]
RP   IDENTIFICATION IN THE CPC COMPLEX, FUNCTION OF THE CPC COMPLEX, INDUCTION,
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-892; SER-893 AND SER-894.
RX   PubMed=12925766; DOI=10.1091/mbc.e02-11-0769;
RA   Honda R., Korner R., Nigg E.A.;
RT   "Exploring the functional interactions between Aurora B, INCENP, and
RT   survivin in mitosis.";
RL   Mol. Biol. Cell 14:3325-3341(2003).
RN   [9]
RP   INTERACTION WITH BIRC5.
RX   PubMed=14610074; DOI=10.1074/jbc.m311299200;
RA   Wheatley S.P., Henzing A.J., Dodson H., Khaled W., Earnshaw W.C.;
RT   "Aurora-B phosphorylation in vitro identifies a residue of survivin that is
RT   essential for its localization and binding to inner centromere protein
RT   (INCENP) in vivo.";
RL   J. Biol. Chem. 279:5655-5660(2004).
RN   [10]
RP   INTERACTION WITH CDCA8.
RX   PubMed=15249581; DOI=10.1083/jcb.200404001;
RA   Gassmann R., Carvalho A., Henzing A.J., Ruchaud S., Hudson D.F., Honda R.,
RA   Nigg E.A., Gerloff D.L., Earnshaw W.C.;
RT   "Borealin: a novel chromosomal passenger required for stability of the
RT   bipolar mitotic spindle.";
RL   J. Cell Biol. 166:179-191(2004).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263 AND SER-275, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [12]
RP   INTERACTION WITH EVI5.
RX   PubMed=16764853; DOI=10.1016/j.yexcr.2006.03.032;
RA   Faitar S.L., Sossey-Alaoui K., Ranalli T.A., Cowell J.K.;
RT   "EVI5 protein associates with the INCENP-aurora B kinase-survivin
RT   chromosomal passenger complex and is involved in the completion of
RT   cytokinesis.";
RL   Exp. Cell Res. 312:2325-2335(2006).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16760428; DOI=10.1091/mbc.e06-03-0240;
RA   Qi W., Tang Z., Yu H.;
RT   "Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is
RT   required for the kinetochore localization of Plk1.";
RL   Mol. Biol. Cell 17:3705-3716(2006).
RN   [14]
RP   INTERACTION WITH BIRC5 AND CDCA8.
RX   PubMed=16571674; DOI=10.1091/mbc.e05-12-1133;
RA   Klein U.R., Nigg E.A., Gruneberg U.;
RT   "Centromere targeting of the chromosomal passenger complex requires a
RT   ternary subcomplex of borealin, survivin, and the N-terminal domain of
RT   INCENP.";
RL   Mol. Biol. Cell 17:2547-2558(2006).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-239; SER-263; SER-269;
RP   SER-275; SER-306; SER-400; THR-406; SER-476 AND SER-899, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-119; SER-148; THR-239;
RP   THR-292; SER-296; SER-306; SER-312; SER-314; SER-446; SER-510; SER-514;
RP   SER-828; SER-831; THR-832; SER-894; SER-899 AND SER-914, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263; SER-828 AND SER-899, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-197; THR-199; THR-213;
RP   SER-214; THR-239; SER-306; SER-314; SER-828; SER-831; THR-832 AND SER-899,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   INTERACTION WITH CBX5; POGZ AND AURKB, AND MUTAGENESIS OF VAL-169 AND
RP   ILE-171.
RX   PubMed=20562864; DOI=10.1038/ncb2075;
RA   Nozawa R.S., Nagao K., Masuda H.T., Iwasaki O., Hirota T., Nozaki N.,
RA   Kimura H., Obuse C.;
RT   "Human POGZ modulates dissociation of HP1alpha from mitotic chromosome arms
RT   through Aurora B activation.";
RL   Nat. Cell Biol. 12:719-727(2010).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-119; SER-143; THR-239;
RP   SER-263; SER-275; THR-292; SER-312; SER-314; SER-330 AND SER-899, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   INTERACTION WITH JTB.
RX   PubMed=21225229; DOI=10.3892/ijo.2011.900;
RA   Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.;
RT   "PAR, a protein involved in the cell cycle, is functionally related to
RT   chromosomal passenger proteins.";
RL   Int. J. Oncol. 38:777-785(2011).
RN   [24]
RP   FUNCTION, INTERACTION WITH CBX1; CBX3 AND CBX5, AND MUTAGENESIS OF PRO-167;
RP   VAL-169 AND ILE-171.
RX   PubMed=21346195; DOI=10.1091/mbc.e11-01-0009;
RA   Kang J., Chaudhary J., Dong H., Kim S., Brautigam C.A., Yu H.;
RT   "Mitotic centromeric targeting of HP1 and its binding to Sgo1 are
RT   dispensable for sister-chromatid cohesion in human cells.";
RL   Mol. Biol. Cell 22:1181-1190(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263; SER-306; SER-314 AND
RP   SER-828, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-72; SER-119; SER-263;
RP   SER-275; THR-292; SER-306; SER-446; SER-894; SER-899 AND SER-914, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   INTERACTION WITH AURKC, FUNCTION, AND PHOSPHORYLATION AT THR-892; SER-893
RP   AND SER-894.
RX   PubMed=27332895; DOI=10.1371/journal.pone.0157305;
RA   Sasai K., Katayama H., Hawke D.H., Sen S.;
RT   "Aurora-C interactions with survivin and INCENP reveal shared and distinct
RT   features compared with Aurora-B chromosome passenger protein complex.";
RL   PLoS ONE 11:E0157305-E0157305(2016).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 3-46, INTERACTION WITH CDCA8 AND
RP   BIRC5, AND MUTAGENESIS OF PHE-22; LEU-34; GLU-35; GLU-36; GLU-39 AND
RP   GLU-40.
RX   PubMed=17956729; DOI=10.1016/j.cell.2007.07.045;
RA   Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., Conti E.;
RT   "Structure of a Survivin-Borealin-INCENP core complex reveals how
RT   chromosomal passengers travel together.";
RL   Cell 131:271-285(2007).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 835-903 IN COMPLEX WITH AURKB.
RX   PubMed=22920039; DOI=10.1021/jm3008954;
RA   Elkins J.M., Santaguida S., Musacchio A., Knapp S.;
RT   "Crystal structure of human aurora B in complex with INCENP and VX-680.";
RL   J. Med. Chem. 55:7841-7848(2012).
CC   -!- FUNCTION: Component of the chromosomal passenger complex (CPC), a
CC       complex that acts as a key regulator of mitosis. The CPC complex has
CC       essential functions at the centromere in ensuring correct chromosome
CC       alignment and segregation and is required for chromatin-induced
CC       microtubule stabilization and spindle assembly. Acts as a scaffold
CC       regulating CPC localization and activity. The C-terminus associates
CC       with AURKB or AURKC, the N-terminus associated with BIRC5/survivin and
CC       CDCA8/borealin tethers the CPC to the inner centromere, and the
CC       microtubule binding activity within the central SAH domain directs
CC       AURKB/C toward substrates near microtubules (PubMed:15316025,
CC       PubMed:12925766, PubMed:27332895). The flexibility of the SAH domain is
CC       proposed to allow AURKB/C to follow substrates on dynamic microtubules
CC       while ensuring CPC docking to static chromatin (By similarity).
CC       Activates AURKB and AURKC (PubMed:27332895). Required for localization
CC       of CBX5 to mitotic centromeres (PubMed:21346195). Controls the
CC       kinetochore localization of BUB1 (PubMed:16760428).
CC       {ECO:0000250|UniProtKB:P53352, ECO:0000269|PubMed:12925766,
CC       ECO:0000269|PubMed:15316025, ECO:0000269|PubMed:16760428,
CC       ECO:0000269|PubMed:21346195, ECO:0000269|PubMed:27332895}.
CC   -!- SUBUNIT: Component of the chromosomal passenger complex (CPC) composed
CC       of at least BIRC5/survivin, CDCA8/borealin, INCENP, AURKB or AURKC; in
CC       the complex binds directly to AURKB or AURKC via the IN box, and forms
CC       a triple-helix bundle-based subcomplex with BIRC5 and CDCA8 via its N-
CC       terminus (PubMed:17956729, PubMed:27332895). The reported
CC       homodimerization is questioned as the SAH domain is shown to be
CC       monomeric (By similarity). Interacts with H2AZ1 (By similarity).
CC       Interacts with CBX1 and CBX3. Interacts with tubulin beta chain.
CC       Interacts with EVI5. Interacts with CBX5; POGZ and INCENP compete for
CC       interaction with CBX5; regulates INCENP (and probably CPC) localization
CC       to centromeres in interphase and not required for proper mitotic
CC       progression or sister chromatid cohesion. Interacts with POGZ.
CC       Interacts with JTB. {ECO:0000250|UniProtKB:P53352,
CC       ECO:0000250|UniProtKB:Q9WU62, ECO:0000269|PubMed:11139336,
CC       ECO:0000269|PubMed:12925766, ECO:0000269|PubMed:14610074,
CC       ECO:0000269|PubMed:15249581, ECO:0000269|PubMed:15316025,
CC       ECO:0000269|PubMed:16764853, ECO:0000269|PubMed:17956729,
CC       ECO:0000269|PubMed:20562864, ECO:0000269|PubMed:21225229,
CC       ECO:0000269|PubMed:21346195, ECO:0000269|PubMed:22920039,
CC       ECO:0000269|PubMed:27332895, ECO:0000269|PubMed:9864353}.
CC   -!- INTERACTION:
CC       Q9NQS7; O14965: AURKA; NbExp=2; IntAct=EBI-307907, EBI-448680;
CC       Q9NQS7; Q96GD4: AURKB; NbExp=19; IntAct=EBI-307907, EBI-624291;
CC       Q9NQS7; Q9UQB9: AURKC; NbExp=17; IntAct=EBI-307907, EBI-3926851;
CC       Q9NQS7; O15392: BIRC5; NbExp=10; IntAct=EBI-307907, EBI-518823;
CC       Q9NQS7; P45973: CBX5; NbExp=11; IntAct=EBI-307907, EBI-78219;
CC       Q9NQS7; Q53HL2: CDCA8; NbExp=5; IntAct=EBI-307907, EBI-979174;
CC       Q9NQS7-1; O14965: AURKA; NbExp=2; IntAct=EBI-15767972, EBI-448680;
CC       Q9NQS7-1; Q96GD4: AURKB; NbExp=2; IntAct=EBI-15767972, EBI-624291;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11453556}.
CC       Chromosome, centromere {ECO:0000269|PubMed:11453556,
CC       ECO:0000269|PubMed:12925766, ECO:0000269|PubMed:15316025,
CC       ECO:0000269|PubMed:16760428}. Cytoplasm, cytoskeleton, spindle
CC       {ECO:0000269|PubMed:11453556, ECO:0000269|PubMed:15316025}. Midbody
CC       {ECO:0000269|PubMed:15316025}. Chromosome, centromere, kinetochore
CC       {ECO:0000269|PubMed:14610074}. Note=Colocalized at synaptonemal complex
CC       central element from zygotene up to late pachytene when it begins to
CC       relocalize to heterochromatic chromocenters. Colocalizes with AURKB at
CC       a connecting strand traversing the centromere region and joining sister
CC       kinetochores, in metaphase II centromeres. This strand disappears at
CC       the metaphase II/anaphase II transition and relocalizes to the spindle
CC       midzone (By similarity). Colocalizes with AURKB at mitotic chromosomes
CC       (PubMed:11453556). Localizes to inner kinetochore (PubMed:16760428).
CC       Localizes on chromosome arms and inner centromeres from prophase
CC       through metaphase and then transferring to the spindle midzone and
CC       midbody from anaphase through cytokinesis (PubMed:15316025). Cocalizes
CC       to the equatorial cell cortex at anaphase (PubMed:11453556).
CC       {ECO:0000250|UniProtKB:Q9WU62, ECO:0000269|PubMed:11453556,
CC       ECO:0000269|PubMed:15316025, ECO:0000269|PubMed:16760428}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NQS7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NQS7-2; Sequence=VSP_035651;
CC   -!- DOMAIN: The IN box mediates interaction with AURKB and AURKC.
CC       {ECO:0000250|UniProtKB:O13024, ECO:0000269|PubMed:27332895}.
CC   -!- DOMAIN: The SAH (single alpha-helix) region is characterized by a high
CC       content of charged residues which are predicted to stabilize the alpha-
CC       helical structure by ionic bonds. It can refold after extension
CC       suggesting an in vivo force-dependent function. The isolated SAH domain
CC       is monomeric. {ECO:0000250|UniProtKB:P53352}.
CC   -!- PTM: Phosphorylation by AURKB or AURKC at its C-terminal part is
CC       important for AURKB or AURKC activation by INCENP.
CC       {ECO:0000269|PubMed:12925766, ECO:0000269|PubMed:15316025,
CC       ECO:0000269|PubMed:27332895}.
CC   -!- SIMILARITY: Belongs to the INCENP family. {ECO:0000305}.
CC   -!- CAUTION: PubMed:11139336 experiments have been carried out partly in
CC       chicken and partly in human. {ECO:0000305}.
CC   -!- CAUTION: Originally predicted to contain a coiled coil domain but shown
CC       to contain a stable SAH domain instead. {ECO:0000250|UniProtKB:P53352}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF282265; AAF87584.1; -; mRNA.
DR   EMBL; AY714053; AAU04398.1; -; mRNA.
DR   EMBL; AP002793; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471076; EAW74004.1; -; Genomic_DNA.
DR   EMBL; BC098576; AAH98576.1; -; mRNA.
DR   CCDS; CCDS31582.1; -. [Q9NQS7-2]
DR   CCDS; CCDS44624.1; -. [Q9NQS7-1]
DR   RefSeq; NP_001035784.1; NM_001040694.1. [Q9NQS7-1]
DR   RefSeq; NP_064623.2; NM_020238.2. [Q9NQS7-2]
DR   PDB; 2QFA; X-ray; 1.40 A; C=1-47.
DR   PDB; 4AF3; X-ray; 2.75 A; D=835-903.
DR   PDB; 5IEH; X-ray; 1.50 A; C=47-55.
DR   PDB; 5IEK; X-ray; 1.80 A; C=47-55.
DR   PDB; 6GR8; X-ray; 1.75 A; B=835-903.
DR   PDB; 6GR9; X-ray; 2.25 A; B=835-903.
DR   PDB; 6YIE; X-ray; 3.49 A; C/F=1-58.
DR   PDB; 6YIF; X-ray; 1.81 A; C=7-57.
DR   PDB; 6YIH; X-ray; 2.55 A; C=5-80.
DR   PDBsum; 2QFA; -.
DR   PDBsum; 4AF3; -.
DR   PDBsum; 5IEH; -.
DR   PDBsum; 5IEK; -.
DR   PDBsum; 6GR8; -.
DR   PDBsum; 6GR9; -.
DR   PDBsum; 6YIE; -.
DR   PDBsum; 6YIF; -.
DR   PDBsum; 6YIH; -.
DR   AlphaFoldDB; Q9NQS7; -.
DR   SMR; Q9NQS7; -.
DR   BioGRID; 109831; 73.
DR   ComplexPortal; CPX-116; Chromosomal passenger complex.
DR   CORUM; Q9NQS7; -.
DR   DIP; DIP-31304N; -.
DR   IntAct; Q9NQS7; 30.
DR   MINT; Q9NQS7; -.
DR   STRING; 9606.ENSP00000378295; -.
DR   BindingDB; Q9NQS7; -.
DR   ChEMBL; CHEMBL3430907; -.
DR   ChEMBL; CHEMBL4106141; -.
DR   DrugBank; DB07340; Reversine.
DR   GlyGen; Q9NQS7; 3 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; Q9NQS7; -.
DR   PhosphoSitePlus; Q9NQS7; -.
DR   SwissPalm; Q9NQS7; -.
DR   BioMuta; INCENP; -.
DR   DMDM; 212276501; -.
DR   EPD; Q9NQS7; -.
DR   jPOST; Q9NQS7; -.
DR   MassIVE; Q9NQS7; -.
DR   MaxQB; Q9NQS7; -.
DR   PaxDb; Q9NQS7; -.
DR   PeptideAtlas; Q9NQS7; -.
DR   ProteomicsDB; 82181; -. [Q9NQS7-1]
DR   ProteomicsDB; 82182; -. [Q9NQS7-2]
DR   Antibodypedia; 4598; 199 antibodies from 30 providers.
DR   DNASU; 3619; -.
DR   Ensembl; ENST00000278849.4; ENSP00000278849.4; ENSG00000149503.13. [Q9NQS7-2]
DR   Ensembl; ENST00000394818.8; ENSP00000378295.3; ENSG00000149503.13. [Q9NQS7-1]
DR   GeneID; 3619; -.
DR   KEGG; hsa:3619; -.
DR   MANE-Select; ENST00000394818.8; ENSP00000378295.3; NM_001040694.2; NP_001035784.1.
DR   UCSC; uc001nsw.2; human. [Q9NQS7-1]
DR   AGR; HGNC:6058; -.
DR   CTD; 3619; -.
DR   DisGeNET; 3619; -.
DR   GeneCards; INCENP; -.
DR   HGNC; HGNC:6058; INCENP.
DR   HPA; ENSG00000149503; Tissue enhanced (bone).
DR   MIM; 604411; gene.
DR   neXtProt; NX_Q9NQS7; -.
DR   OpenTargets; ENSG00000149503; -.
DR   PharmGKB; PA29868; -.
DR   VEuPathDB; HostDB:ENSG00000149503; -.
DR   eggNOG; KOG4456; Eukaryota.
DR   GeneTree; ENSGT00730000111073; -.
DR   HOGENOM; CLU_015997_0_0_1; -.
DR   InParanoid; Q9NQS7; -.
DR   OMA; SNDYGMD; -.
DR   OrthoDB; 3094173at2759; -.
DR   PhylomeDB; Q9NQS7; -.
DR   TreeFam; TF101172; -.
DR   PathwayCommons; Q9NQS7; -.
DR   Reactome; R-HSA-141444; Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2500257; Resolution of Sister Chromatid Cohesion.
DR   Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   Reactome; R-HSA-68877; Mitotic Prometaphase.
DR   Reactome; R-HSA-9648025; EML4 and NUDC in mitotic spindle formation.
DR   SignaLink; Q9NQS7; -.
DR   SIGNOR; Q9NQS7; -.
DR   BioGRID-ORCS; 3619; 784 hits in 1165 CRISPR screens.
DR   ChiTaRS; INCENP; human.
DR   EvolutionaryTrace; Q9NQS7; -.
DR   GeneWiki; INCENP; -.
DR   GenomeRNAi; 3619; -.
DR   Pharos; Q9NQS7; Tbio.
DR   PRO; PR:Q9NQS7; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9NQS7; protein.
DR   Bgee; ENSG00000149503; Expressed in ventricular zone and 119 other tissues.
DR   ExpressionAtlas; Q9NQS7; baseline and differential.
DR   Genevisible; Q9NQS7; HS.
DR   GO; GO:0000801; C:central element; IEA:Ensembl.
DR   GO; GO:0010369; C:chromocenter; IEA:Ensembl.
DR   GO; GO:0032133; C:chromosome passenger complex; IPI:ComplexPortal.
DR   GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0000776; C:kinetochore; IDA:UniProtKB.
DR   GO; GO:0000800; C:lateral element; IEA:Ensembl.
DR   GO; GO:1990385; C:meiotic spindle midzone; IBA:GO_Central.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:ComplexPortal.
DR   GO; GO:0030496; C:midbody; IDA:HPA.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005721; C:pericentric heterochromatin; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0005819; C:spindle; IDA:UniProtKB.
DR   GO; GO:0140677; F:molecular function activator activity; IPI:DisProt.
DR   GO; GO:0007059; P:chromosome segregation; IMP:UniProtKB.
DR   GO; GO:0051257; P:meiotic spindle midzone assembly; IBA:GO_Central.
DR   GO; GO:0051310; P:metaphase plate congression; IBA:GO_Central.
DR   GO; GO:0000278; P:mitotic cell cycle; NAS:ComplexPortal.
DR   GO; GO:0000281; P:mitotic cytokinesis; IMP:UniProtKB.
DR   GO; GO:0051256; P:mitotic spindle midzone assembly; NAS:ComplexPortal.
DR   GO; GO:0007052; P:mitotic spindle organization; NAS:ComplexPortal.
DR   GO; GO:1902425; P:positive regulation of attachment of mitotic spindle microtubules to kinetochore; NAS:ComplexPortal.
DR   GO; GO:0090267; P:positive regulation of mitotic cell cycle spindle assembly checkpoint; NAS:ComplexPortal.
DR   GO; GO:1903490; P:positive regulation of mitotic cytokinesis; NAS:ComplexPortal.
DR   GO; GO:1901970; P:positive regulation of mitotic sister chromatid separation; NAS:ComplexPortal.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; NAS:ComplexPortal.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:ComplexPortal.
DR   DisProt; DP02390; -.
DR   Gene3D; 1.20.5.3600; -; 1.
DR   Gene3D; 6.10.250.2990; -; 1.
DR   IDEAL; IID00224; -.
DR   InterPro; IPR022006; INCENP_N.
DR   InterPro; IPR005635; Inner_centromere_prot_ARK-bd.
DR   PANTHER; PTHR13142; INNER CENTROMERE PROTEIN; 1.
DR   PANTHER; PTHR13142:SF1; INNER CENTROMERE PROTEIN; 1.
DR   Pfam; PF03941; INCENP_ARK-bind; 1.
DR   Pfam; PF12178; INCENP_N; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Cell division; Centromere;
KW   Chromosome; Chromosome partition; Cytoplasm; Cytoskeleton; Kinetochore;
KW   Microtubule; Mitosis; Nucleus; Phosphoprotein; Reference proteome.
FT   CHAIN           1..918
FT                   /note="Inner centromere protein"
FT                   /id="PRO_0000084201"
FT   REGION          48..105
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          124..248
FT                   /note="Interaction with CBX5"
FT                   /evidence="ECO:0000269|PubMed:21346195"
FT   REGION          138..159
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          190..253
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          285..316
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          371..489
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          531..765
FT                   /note="SAH"
FT                   /evidence="ECO:0000250|UniProtKB:P53352"
FT   REGION          607..640
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          660..740
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          754..787
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          822..897
FT                   /note="Interaction with AURKC"
FT                   /evidence="ECO:0000269|PubMed:27332895"
FT   REGION          826..900
FT                   /note="IN box"
FT                   /evidence="ECO:0000305"
FT   REGION          826..845
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           167..171
FT                   /note="PXVXL/I motif"
FT                   /evidence="ECO:0000305|PubMed:21346195"
FT   COMPBIAS        70..84
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        141..159
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        190..216
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        289..316
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        393..433
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        435..461
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        754..784
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         72
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         119
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         143
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         148
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         150
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WU62"
FT   MOD_RES         195
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15316025"
FT   MOD_RES         197
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         199
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         213
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         214
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         219
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WU62"
FT   MOD_RES         239
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         263
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         269
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         275
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         292
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         296
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         306
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         312
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         314
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         330
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         400
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         406
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         446
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         476
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         478
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WU62"
FT   MOD_RES         480
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WU62"
FT   MOD_RES         510
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         514
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         828
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         831
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         832
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         892
FT                   /note="Phosphothreonine; by AURKB and AURKC"
FT                   /evidence="ECO:0000269|PubMed:12925766,
FT                   ECO:0000269|PubMed:27332895"
FT   MOD_RES         893
FT                   /note="Phosphoserine; by AURKB and AURKC"
FT                   /evidence="ECO:0000269|PubMed:12925766,
FT                   ECO:0000269|PubMed:27332895"
FT   MOD_RES         894
FT                   /note="Phosphoserine; by AURKB and AURKC"
FT                   /evidence="ECO:0000269|PubMed:12925766,
FT                   ECO:0000269|PubMed:27332895, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         899
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         914
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         532..535
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11453556"
FT                   /id="VSP_035651"
FT   VARIANT         2
FT                   /note="G -> V (in dbSNP:rs1792947)"
FT                   /id="VAR_047127"
FT   VARIANT         100
FT                   /note="R -> H (in dbSNP:rs12281503)"
FT                   /id="VAR_047128"
FT   VARIANT         137
FT                   /note="A -> V (in dbSNP:rs34441559)"
FT                   /id="VAR_047129"
FT   VARIANT         506
FT                   /note="M -> T (in dbSNP:rs2277283)"
FT                   /id="VAR_047130"
FT   VARIANT         644
FT                   /note="E -> D (in dbSNP:rs7129085)"
FT                   /evidence="ECO:0000269|PubMed:11453556,
FT                   ECO:0000269|PubMed:15316025, ECO:0000269|PubMed:15489334"
FT                   /id="VAR_047131"
FT   MUTAGEN         22
FT                   /note="F->R: Loss of binding to CDCA8 and BIRC5; when
FT                   associated with R-34."
FT                   /evidence="ECO:0000269|PubMed:17956729"
FT   MUTAGEN         34
FT                   /note="L->R: Loss of binding to CDCA8 and BIRC5; when
FT                   associated with R-22."
FT                   /evidence="ECO:0000269|PubMed:17956729"
FT   MUTAGEN         35
FT                   /note="E->R: Loss of localization to the central spindle
FT                   and midbody in anaphase or cytokinesis; when associated
FT                   with R-36; R-39 and R-40."
FT                   /evidence="ECO:0000269|PubMed:17956729"
FT   MUTAGEN         36
FT                   /note="E->R: Loss of localization to the central spindle
FT                   and midbody in anaphase or cytokinesis; when associated
FT                   with R-35; R-39 and R-40."
FT                   /evidence="ECO:0000269|PubMed:17956729"
FT   MUTAGEN         39
FT                   /note="E->R: Loss of localization to the central spindle
FT                   and midbody in anaphase or cytokinesis; when associated
FT                   with R-35; R-36 and R-40."
FT                   /evidence="ECO:0000269|PubMed:17956729"
FT   MUTAGEN         40
FT                   /note="E->R: Loss of localization to the central spindle
FT                   and midbody in anaphase or cytokinesis; when associated
FT                   with R-35; R-36 and R-39."
FT                   /evidence="ECO:0000269|PubMed:17956729"
FT   MUTAGEN         167
FT                   /note="P->A: Decreases interaction with CBX5, abolishes
FT                   localization to centromeres in interphase; when associated
FT                   with A-169 and A-171."
FT                   /evidence="ECO:0000269|PubMed:21346195"
FT   MUTAGEN         169
FT                   /note="V->A: Decreases interaction with CBX5, abolishes
FT                   localization to centromeres in interphase; when associated
FT                   with A-167 and A-171."
FT                   /evidence="ECO:0000269|PubMed:21346195"
FT   MUTAGEN         169
FT                   /note="V->E: Abolishes interaction with CBX5."
FT                   /evidence="ECO:0000269|PubMed:20562864"
FT   MUTAGEN         171
FT                   /note="I->A: Decreases interaction with CBX5, abolishes
FT                   localization to centromeres in interphase; when associated
FT                   with A-167 and A-169."
FT                   /evidence="ECO:0000269|PubMed:21346195"
FT   MUTAGEN         171
FT                   /note="I->E: Abolishes interaction with CBX5 and AURKB."
FT                   /evidence="ECO:0000269|PubMed:20562864"
FT   CONFLICT        715
FT                   /note="Q -> QERREQ (in Ref. 1; AAF87584)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        804..806
FT                   /note="YQM -> SPI (in Ref. 1; AAF87584)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        812
FT                   /note="R -> K (in Ref. 1; AAF87584)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        816
FT                   /note="K -> Q (in Ref. 1; AAF87584)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        820
FT                   /note="D -> H (in Ref. 1; AAF87584)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        861
FT                   /note="H -> Q (in Ref. 1; AAF87584)"
FT                   /evidence="ECO:0000305"
FT   HELIX           8..10
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   HELIX           11..28
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   HELIX           30..45
FT                   /evidence="ECO:0007829|PDB:2QFA"
FT   HELIX           844..846
FT                   /evidence="ECO:0007829|PDB:6GR8"
FT   HELIX           848..860
FT                   /evidence="ECO:0007829|PDB:6GR8"
FT   HELIX           865..869
FT                   /evidence="ECO:0007829|PDB:6GR8"
FT   HELIX           877..881
FT                   /evidence="ECO:0007829|PDB:6GR8"
FT   HELIX           886..889
FT                   /evidence="ECO:0007829|PDB:6GR8"
FT   HELIX           893..895
FT                   /evidence="ECO:0007829|PDB:6GR8"
SQ   SEQUENCE   918 AA;  105429 MW;  644D081DCC9035E8 CRC64;
     MGTTAPGPIH LLELCDQKLM EFLCNMDNKD LVWLEEIQEE AERMFTREFS KEPELMPKTP
     SQKNRRKKRR ISYVQDENRD PIRRRLSRRK SRSSQLSSRR LRSKDSVEKL ATVVGENGSV
     LRRVTRAAAA AAAATMALAA PSSPTPESPT MLTKKPEDNH TQCQLVPVVE IGISERQNAE
     QHVTQLMSTE PLPRTLSPTP ASATAPTSQG IPTSDEESTP KKSKARILES ITVSSLMATP
     QDPKGQGVGT GRSASKLRIA QVSPGPRDSP AFPDSPWRER VLAPILPDNF STPTGSRTDS
     QSVRHSPIAP SSPSPQVLAQ KYSLVAKQES VVRRASRRLA KKTAEEPAAS GRIICHSYLE
     RLLNVEVPQK VGSEQKEPPE EAEPVAAAEP EVPENNGNNS WPHNDTEIAN STPNPKPAAS
     SPETPSAGQQ EAKTDQADGP REPPQSARRK RSYKQAVSEL DEEQHLEDEE LQPPRSKTPS
     SPCPASKVVR PLRTFLHTVQ RNQMLMTPTS APRSVMKSFI KRNTPLRMDP KCSFVEKERQ
     RLENLRRKEE AEQLRRQKVE EDKRRRLEEV KLKREERLRK VLQARERVEQ MKEEKKKQIE
     QKFAQIDEKT EKAKEERLAE EKAKKKAAAK KMEEVEARRK QEEEARRLRW LQQEEEERRH
     QELLQKKKEE EQERLRKAAE AKRLAEQREQ ERREQERREQ ERREQERREQ ERREQERQLA
     EQERRREQER LQAERELQER EKALRLQKEQ LQRELEEKKK KEEQQRLAER QLQEEQEKKA
     KEAAGASKAL NVTVDVQSPA CTSYQMTPQG HRAPPKINPD NYGMDLNSDD STDDEAHPRK
     PIPTWARGTP LSQAIIHQYY HPPNLLELFG TILPLDLEDI FKKSKPRYHK RTSSAVWNSP
     PLQGARVPSS LAYSLKKH
//
